


Accepted Manuscript

Galactosylated chitosan Triptolide nanoparticles for overcoming hepatocellular carcinoma: Enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms

Yan-Qiong Zhang, Yan Shen, Ming-Mei Liao, Xia Mao, Gu-Jie Mi, Chen You, Qiu-Yan Guo, Wei-Jie Li, Xiao-Yue Wang, Na Lin, Thomas J. Webster



PII: S1549-9634(18)30519-7

DOI: doi:[10.1016/j.nano.2018.09.002](https://doi.org/10.1016/j.nano.2018.09.002)

Reference: NANO 1866

To appear in: *Nanomedicine: Nanotechnology, Biology, and Medicine*

Received date: 11 July 2018

Revised date: 22 August 2018

Accepted date: 3 September 2018

Please cite this article as: Yan-Qiong Zhang, Yan Shen, Ming-Mei Liao, Xia Mao, Gu-Jie Mi, Chen You, Qiu-Yan Guo, Wei-Jie Li, Xiao-Yue Wang, Na Lin, Thomas J. Webster, Galactosylated chitosan Triptolide nanoparticles for overcoming hepatocellular carcinoma: Enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms. *Nano* (2018), doi:[10.1016/j.nano.2018.09.002](https://doi.org/10.1016/j.nano.2018.09.002)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Title: Galactosylated Chitosan Triptolide Nanoparticles for Overcoming Hepatocellular Carcinoma: Enhanced Therapeutic Efficacy, Low Toxicity, and Validated Network Regulatory Mechanisms

Running Title: GC-TP-NPs for HCC targeting therapy

Authors: Yan-Qiong Zhang^{1#}, Yan Shen^{2#}, Ming-Mei Liao³, Xia Mao¹, Gu-Jie Mi⁴, Chen You⁵, Qiu-Yan Guo¹, Wei-Jie Li¹, Xiao-Yue Wang¹, Na Lin^{1*} and Thomas J. Webster^{4*}

Affiliation:

1, Institute of Chinese Materials Medical, China Academy of Chinese Medical Sciences, Beijing 100700, China; 2, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, 210009, China; 3, Key Laboratory of Nanobiological Technology of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China; 4, Department of Chemical Engineering, Northeastern University, Boston 02115, USA; and 5, Jiangsu Provincial Xuzhou Pharmaceutical Vocational College, Xuzhou, 221116, China.

[#]These authors contributed equally to this study.

***Corresponding authors:** Prof. Thomas J Webster & Prof. Na Lin

E-mail: th.webster@neu.edu & nlin@icmm.ac.cn

Phone: +861064014411-2869

Fax: +861064013996

Funding

This study was supported by the National Natural Science Foundation of China (No. 81673834), Beijing Nova Program (No. Z1511000003150126), and the Fundamental Research Funds for the Central Public Welfare Research Institutes (No. Z2017082&L2017018).

Conflicts of interest

The authors do not have any conflicts of interest with the content of the manuscript.

Word count for the abstract: 150; Manuscript word count (including text and figure legends): 4999; Number of references: 44; and Number of figures: 5.

Download English Version:

<https://daneshyari.com/en/article/11016206>

Download Persian Version:

<https://daneshyari.com/article/11016206>

[Daneshyari.com](https://daneshyari.com)